Common drug could impact breast cancer treatment
Investigators explored the effects of noncancer drugs in patients with breast cancer.
In a study published in Cancer Medicine, the investigators used the data from 19 clinical trials to determine survival outcomes and adverse events among more than 23,000 patients with breast cancer.
The use of proton pump inhibitors was found to be linked to worse overall and progression-free survival. Further, proton pump inhibitors, beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and calcium channel blockers all increased the risk of drug-related adverse events.
The investigators stated: “Although our analysis does not establish direct mechanistic links, it raises important questions about routinely used concomitant medicines and the need for more personalized approaches to care that balance their potential risks and benefits.”
Read more: Cancer Medicine
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.